

CITATION REPORT

List of articles citing

PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances

DOI: 10.1042/bj20112092

Biochemical Journal, 2012, 442, 465-81.

Source: <https://exaly.com/paper-pdf/53131897/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 183 | Novel Agents and Emerging Strategies for Targeting the B-Cell Receptor Pathway in CLL. 2012 , 4, e2012067 | | 13 |
| 182 | Akt and mTOR in B Cell Activation and Differentiation. <i>Frontiers in Immunology</i> , 2012 , 3, 228 | 8.4 | 127 |
| 181 | Regulation of T cell homeostasis and responses by pten. <i>Frontiers in Immunology</i> , 2012 , 3, 151 | 8.4 | 34 |
| 180 | Use of whole exome and genome sequencing in the identification of genetic causes of primary immunodeficiencies. 2012 , 12, 623-8 | | 50 |
| 179 | Beta-testing of PI3-kinase inhibitors: is beta better?. 2012 , 2, 393-4 | | 3 |
| 178 | Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?. 2012 , 17, 1562-73 | | 33 |
| 177 | Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities. <i>Frontiers in Immunology</i> , 2012 , 3, 226 | 8.4 | 12 |
| 176 | Does the PI3K pathway promote or antagonize regulatory T cell development and function?. <i>Frontiers in Immunology</i> , 2012 , 3, 244 | 8.4 | 35 |
| 175 | Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. <i>Frontiers in Immunology</i> , 2012 , 3, 256 | 8.4 | 74 |
| 174 | All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. <i>Frontiers in Immunology</i> , 2012 , 3, 312 | 8.4 | 32 |
| 173 | Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 4684-91 | 2.2 | 124 |
| 172 | Constitutive Akt1 signals attenuate B-cell receptor signaling and proliferation, but enhance B-cell migration and effector function. <i>European Journal of Immunology</i> , 2012 , 42, 3381-93 | 6.1 | 6 |
| 171 | PI3K δ is essential for tumor clearance mediated by cytotoxic T lymphocytes. <i>PLoS ONE</i> , 2012 , 7, e40852 | 3.7 | 29 |
| 170 | Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. 2012 , 2012, 88-96 | | 30 |
| 169 | Calming down T cell acute leukemia. 2012 , 21, 449-50 | | 4 |
| 168 | Phosphoinositide 3'-kinase inhibition in chronic lymphocytic leukemia. 2013 , 27, 329-39 | | 7 |
| 167 | A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. <i>Acta Pharmacologica Sinica</i> , 2013 , 34, 1201-7 | 8 | 11 |

| | | | |
|-----|--|------|-----|
| 166 | Role of phosphatidylinositol 3,4,5-trisphosphate in cell signaling. 2013 , 991, 105-39 | | 25 |
| 165 | Lipid-mediated Protein Signaling. 2013 , | | 6 |
| 164 | Cross talk between the Akt and p38 β pathways in macrophages downstream of Toll-like receptor signaling. 2013 , 33, 4152-65 | | 54 |
| 163 | Advances in Chronic Lymphocytic Leukemia. 2013 , | | 2 |
| 162 | Towards targeted therapy of chronic lymphocytic leukemia. 2013 , 792, 259-91 | | 10 |
| 161 | Context-specific BAFF-R signaling by the NF- κ B and PI3K pathways. 2013 , 5, 1022-35 | | 56 |
| 160 | Kurarinone regulates immune responses through regulation of the JAK/STAT and TCR-mediated signaling pathways. 2013 , 85, 1134-44 | | 36 |
| 159 | Identifying novel spatiotemporal regulators of innate immunity. 2013 , 55, 3-9 | | 1 |
| 158 | Signaling by the phosphoinositide 3-kinase family in immune cells. <i>Annual Review of Immunology</i> , 2013 , 31, 675-704 | 34.7 | 268 |
| 157 | Targeting pathological B cell receptor signalling in lymphoid malignancies. 2013 , 12, 229-43 | | 286 |
| 156 | Targeting phosphoinositide 3-kinase Γ for the treatment of respiratory diseases. 2013 , 1280, 35-9 | | 48 |
| 155 | EphB and Ephrin-B interactions mediate human mesenchymal stem cell suppression of activated T-cells. 2013 , 22, 2751-64 | | 48 |
| 154 | Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2013 , 17, 921-36 | 6.4 | 11 |
| 153 | B-cell receptor signaling as a driver of lymphoma development and evolution. <i>Seminars in Cancer Biology</i> , 2013 , 23, 410-21 | 12.7 | 142 |
| 152 | Role of inositol poly-phosphatases and their targets in T cell biology. <i>Frontiers in Immunology</i> , 2013 , 4, 288 | 8.4 | 16 |
| 151 | p110 β PI3 kinase pathway: emerging roles in cancer. 2013 , 3, 40 | | 36 |
| 150 | An Emerging Role for PI5P in T Cell Biology. <i>Frontiers in Immunology</i> , 2013 , 4, 80 | 8.4 | 6 |
| 149 | The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. <i>British Journal of Haematology</i> , 2013 , 163, 72-80 | 4.5 | 20 |

| | | |
|-----|---|---------|
| 148 | Selective inhibition of phosphoinositide 3-kinase p110 β preserves lymphocyte function. 2013 , 288, 5718-31 | 53 |
| 147 | TLR4 signaling shapes B cell dynamics via MyD88-dependent pathways and Rac GTPases. 2013 , 191, 3867-75 | 19 |
| 146 | Transition from heterotypic to homotypic PDK1 homodimerization is essential for TCR-mediated NF- κ B activation. 2013 , 190, 4508-15 | 11 |
| 145 | Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. 2013 , 98, 57-64 | 25 |
| 144 | PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma. 2014 , 6, 737-53 | 14 |
| 143 | BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma. 2014 , 2014, 125-34 | 26 |
| 142 | Idelalisib for the treatment of chronic lymphocytic leukemia. 2014 , 2014, 931858 | 3 |
| 141 | Targeting p110 γ in gastrointestinal cancers: attack on multiple fronts. 2014 , 5, 391 | 6 |
| 140 | New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. <i>Clinical Cancer Research</i> , 2014 , 20, 5869-74 | 12.9 43 |
| 139 | Differences in cellular function and viral protein expression between IgM ^{high} and IgM ^{low} B-cells in bovine leukemia virus-infected cattle. 2014 , 95, 1832-1842 | 4 |
| 138 | Advances in subunits of PI3K class I in cancer. 2014 , 46, 169-76 | 12 |
| 137 | Putative roles for PI3K β and δ isoforms in refractory mantle cell lymphoma. 2014 , 131, 218-9 | 1 |
| 136 | PI3K inhibitors as potential therapeutics for autoimmune disease. 2014 , 19, 1195-9 | 23 |
| 135 | PI3K in cancer-stroma interactions: bad in seed and ugly in soil. 2014 , 33, 3083-90 | 47 |
| 134 | PDK1 controls upstream PI3K expression and PIP3 generation. 2014 , 33, 3043-53 | 17 |
| 133 | Innate PI3K p110 β regulates Th1/Th17 development and microbiota-dependent colitis. 2014 , 192, 3958-68 | 42 |
| 132 | Biogenetically Inspired Total Synthesis of (+)-Liphagal: A Potent and Selective Phosphoinositide 3-Kinase [PI3K] Inhibitor from the Marine Sponge Aka coralliphaga. 2014 , 2014, 3443-3450 | 24 |
| 131 | Molecular targets on mast cells and basophils for novel therapies. 2014 , 134, 530-44 | 104 |

| | | | |
|-----|---|------|------|
| 130 | PI3K and cancer: lessons, challenges and opportunities. 2014 , 13, 140-56 | | 1127 |
| 129 | Signaling circuits in early B-cell development. 2014 , 122, 129-75 | | 39 |
| 128 | Agammaglobulinemia. 2014 , 329-346 | | 1 |
| 127 | Doxycycline exerts multiple anti-allergy effects to attenuate murine allergic conjunctivitis and systemic anaphylaxis. 2014 , 91, 359-68 | | 18 |
| 126 | Genetic associations with micronutrient levels identified in immune and gastrointestinal networks. 2014 , 9, 408 | | 11 |
| 125 | Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75. 2014 , 27, 53-67 | | 9 |
| 124 | The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. 2015 , 100, 1495-507 | | 69 |
| 123 | Reduction in Renal Ischemia-Reperfusion Injury in Mice by a Phosphoinositide 3-Kinase p110gamma-Specific Inhibitor. 2015 , 99, 2070-6 | | 7 |
| 122 | Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. <i>Blood</i> , 2015 , 125, 3357-9 | 2.2 | 78 |
| 121 | PI3K signalling in inflammation. 2015 , 1851, 882-97 | | 278 |
| 120 | Development and application of PI3K assays for novel drug discovery. 2015 , 10, 171-86 | | 17 |
| 119 | Transcriptomic profiling of peripheral blood CD4+ T-cells in asthmatics with and without depression. 2015 , 565, 282-7 | | 9 |
| 118 | Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. 2015 , 20, 988-94 | | 31 |
| 117 | Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2015 , 21, 3160-9 | 13.9 | 46 |
| 116 | Cowden's syndrome with immunodeficiency. 2015 , 52, 856-9 | | 38 |
| 115 | Metabolic mysteries of the inflammatory response: T cell polarization and plasticity. 2015 , 34, 3-18 | | 16 |
| 114 | Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies. <i>British Journal of Haematology</i> , 2016 , 175, 55-65 | 4.5 | 11 |
| 113 | Coordinated loss of microRNA group causes defenseless signaling in malignant lymphoma. <i>Scientific Reports</i> , 2015 , 5, 17868 | 4.9 | 11 |

| | | | |
|-----|---|------|-----|
| 112 | The PI3K/Akt/mTOR Pathway. 2016 , 128-135 | | 1 |
| 111 | The Nuclear Zinc Finger Protein Zfat Maintains FoxO1 Protein Levels in Peripheral T Cells by Regulating the Activities of Autophagy and the Akt Signaling Pathway. 2016 , 291, 15282-91 | | 11 |
| 110 | Protein-kinase Inhibitors: A New Treatment Pathway for Autoimmune and Inflammatory Diseases?. 2016 , 12, 91-99 | | 2 |
| 109 | Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy. 2016 , 5, 24-32 | | 24 |
| 108 | PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc. 2016 , 37, 12767-12777 | | 3 |
| 107 | What goes up must come down: A tripartite Dok-3/Grb2/SHIP1 inhibitory module limits BCR signaling. <i>European Journal of Immunology</i> , 2016 , 46, 2507-2511 | 6.1 | 2 |
| 106 | Enantioselective Total Synthesis of (-)-Siphonodictyal B and (+)-8-epi-Siphonodictyal B with Phosphatidylinositol 3-Kinase (PI3K) Inhibitory Activity. 2016 , 2016, 5659-5666 | | 6 |
| 105 | Antigen-affinity controls pre-germinal center B cell selection by promoting Mcl-1 induction through BAFF receptor signaling. <i>Scientific Reports</i> , 2016 , 6, 35673 | 4.9 | 9 |
| 104 | Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer. 2016 , 45, 21-31 | | 9 |
| 103 | PI3K promotes CD4(+) T-cell interactions with antigen-presenting cells by increasing LFA-1 binding to ICAM-1. 2016 , 94, 486-95 | | 13 |
| 102 | F-actin remodeling defects as revealed in primary immunodeficiency disorders. 2016 , 164, 34-42 | | 7 |
| 101 | ETP-46321, a dual p110 α /class IA phosphoinositide 3-kinase inhibitor modulates T lymphocyte activation and collagen-induced arthritis. 2016 , 106, 56-69 | | 11 |
| 100 | Follicular Helper T Cells. <i>Annual Review of Immunology</i> , 2016 , 34, 335-68 | 34.7 | 629 |
| 99 | Molecules in medicine mini-review: isoforms of PI3K in biology and disease. 2016 , 94, 5-11 | | 89 |
| 98 | Protein-kinase inhibitors: A new treatment pathway for autoimmune and inflammatory diseases?. 2016 , 12, 91-9 | | 11 |
| 97 | miR-138-1* regulates aflatoxin B1-induced malignant transformation of BEAS-2B cells by targeting PDK1. 2016 , 90, 1239-49 | | 24 |
| 96 | Targeted Therapy and Immunosuppression in the Tumor Microenvironment. 2017 , 3, 19-27 | | 32 |
| 95 | Simultaneous Inhibition of PI3K α and PI3K β Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF- κ B and AKT. 2017 , 31, 64-78 | | 96 |

| | | | |
|----|--|------|------|
| 94 | AKT/PKB Signaling: Navigating the Network. 2017 , 169, 381-405 | | 1570 |
| 93 | Design and Synthesis of Soluble and Cell-Permeable PI3K Inhibitors for Long-Acting Inhaled Administration. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 5057-5071 | 8.3 | 14 |
| 92 | Puquitinib, a novel orally available PI3K Inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. 2017 , 108, 1476-1484 | | 20 |
| 91 | B-cell-intrinsic function of TAPP adaptors in controlling germinal center responses and autoantibody production in mice. <i>European Journal of Immunology</i> , 2017 , 47, 280-290 | 6.1 | 7 |
| 90 | Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. 2017 , 10, 1069-1076 | | 6 |
| 89 | D-chiro inositol phosphoglycans in preeclampsia: Where are we, where are we going?. 2017 , 124, 1-7 | | 5 |
| 88 | Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia. 2017 , 26, 1249-1265 | | 27 |
| 87 | Development of highly sensitive cell-based AKT kinase ELISA for monitoring PI3K beta activity and compound efficacy. 2017 , 38, 663-674 | | 0 |
| 86 | Cancer Biology and the Principles of Targeted Cancer Drug Discovery. 2017 , 1-38 | | 1 |
| 85 | Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFN-driven lupus nephritis. 2017 , 2, e90111 | | 48 |
| 84 | Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 2227-2245 | 8.3 | 119 |
| 83 | MiR221 promotes precursor B-cell retention in the bone marrow by amplifying the PI3K-signaling pathway in mice. <i>European Journal of Immunology</i> , 2018 , 48, 975-989 | 6.1 | 6 |
| 82 | First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13). <i>European Journal of Cancer</i> , 2018 , 96, 6-16 | 7.5 | 35 |
| 81 | Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. <i>BioDrugs</i> , 2018 , 32, 221-231 | 7.9 | 12 |
| 80 | Distinct roles for phosphoinositide 3-kinases β and δ in malignant B cell migration. <i>Leukemia</i> , 2018 , 32, 1958-1969 | 10.7 | 28 |
| 79 | Total Syntheses of Liphagal: A Potent and Selective Phosphoinositide 3-Kinase (PI3K) Inhibitor from the Marine Sponge Aka coralliphaga. <i>Heterocycles</i> , 2018 , 96, 3 | 0.8 | 4 |
| 78 | The PI3K/AKT signaling pathway in regulatory T-cell development, stability, and function. <i>Journal of Leukocyte Biology</i> , 2018 , 103, 1065 | 6.5 | 97 |
| 77 | Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 637-646 | 3.4 | 3 |

| | | | |
|----|--|------|-----|
| 76 | PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer. <i>Aging Male</i> , 2018 , 21, 211-222 | 2.1 | 17 |
| 75 | miR-26a promoted endometrial epithelium cells (EECs) proliferation and induced stromal cells (ESCs) apoptosis via the PTEN-PI3K/AKT pathway in dairy goats. <i>Journal of Cellular Physiology</i> , 2018 , 233, 4688-4706 | 7 | 32 |
| 74 | Isoform-specific activities of the regulatory subunits of phosphatidylinositol 3-kinases - potentially novel therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018 , 22, 869-877 | 6.4 | 6 |
| 73 | T-Cell-Specific Loss of the PI-3-Kinase p110 β Catalytic Subunit Results in Enhanced Cytokine Production and Antitumor Response. <i>Frontiers in Immunology</i> , 2018 , 9, 332 | 8.4 | 8 |
| 72 | Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018 , 9, 1088 | 8.4 | 100 |
| 71 | Pharmacology and Molecular Mechanisms of Antineoplastic Agents for Hematologic Malignancies. 2018 , 849-912 | | 15 |
| 70 | B cell adaptor for PI3-kinase (BCAP) modulates CD8 effector and memory T cell differentiation. <i>Journal of Experimental Medicine</i> , 2018 , 215, 2429-2443 | 16.6 | 15 |
| 69 | Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 183, 428-444 | 4.5 | 129 |
| 68 | Discovery and Optimization of 2-Amino-4-methylquinazoline Derivatives as Highly Potent Phosphatidylinositol 3-Kinase Inhibitors for Cancer Treatment. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 6087-6109 | 8.3 | 22 |
| 67 | Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. <i>Immunological Reviews</i> , 2019 , 291, 190-213 | 11.3 | 40 |
| 66 | For Better or Worse: The Potential for Dose Limiting the On-Target Toxicity of PI 3-Kinase Inhibitors. <i>Biomolecules</i> , 2019 , 9, | 5.9 | 12 |
| 65 | Conformationally restricted quinazoline derivatives as PI3K-selective inhibitors: the design, synthesis and biological evaluation. <i>MedChemComm</i> , 2019 , 10, 413-420 | 5 | 3 |
| 64 | Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2019 , 20, | 6.3 | 28 |
| 63 | PI3K isoforms in cell signalling and vesicle trafficking. <i>Nature Reviews Molecular Cell Biology</i> , 2019 , 20, 515-534 | 48.7 | 165 |
| 62 | Antigen Receptor Function in the Context of the Nanoscale Organization of the B Cell Membrane. <i>Annual Review of Immunology</i> , 2019 , 37, 97-123 | 34.7 | 30 |
| 61 | Parsaclisib, a potent and highly selective PI3K inhibitor, in patients with relapsed or refractory B-cell malignancies. <i>Blood</i> , 2019 , 133, 1742-1752 | 2.2 | 47 |
| 60 | CD147-mediated reprogrammed glycolytic metabolism potentially induces immune escape in the tumor microenvironment (Review). <i>Oncology Reports</i> , 2019 , 41, 2945-2956 | 3.5 | 5 |
| 59 | Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival. <i>American Journal of Transplantation</i> , 2019 , 19, 1305-1314 | 8.7 | 15 |

| | | | |
|----|---|------|----|
| 58 | Suppression of ovarian follicle development by nano TiO is associated with TGF-β-mediated signaling pathways. <i>Journal of Biomedical Materials Research - Part A</i> , 2019 , 107, 414-422 | 5.4 | 7 |
| 57 | The effects of total glucosides of paeony (TGP) and paeoniflorin (Pae) on inflammatory-immune responses in rheumatoid arthritis (RA). <i>Functional Plant Biology</i> , 2019 , 46, 107-117 | 2.7 | 13 |
| 56 | PI3K-p110 α contributes to antibody responses by macrophages in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 451-461 | 10.7 | 7 |
| 55 | Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis [corrected]. <i>Pharmaceutical Research</i> , 2020 , 37, 25 | 4.5 | 9 |
| 54 | Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020 , 65, 51-64 | 12.7 | 35 |
| 53 | Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice. <i>Journal of Chemotherapy</i> , 2020 , 32, 88-97 | 2.3 | 2 |
| 52 | Check Point Inhibitors and Their Role in Immunosuppression in Sepsis. <i>Critical Care Clinics</i> , 2020 , 36, 69-88 | 8.5 | 15 |
| 51 | 'Nur'turing tumor T cell tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity. <i>European Journal of Immunology</i> , 2020 , 50, 1643-1652 | 6.1 | 5 |
| 50 | PI3K β inhibition as a Potential Therapeutic Target in COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 2094 | 8.4 | 15 |
| 49 | Implications of cellular metabolism for immune cell migration. <i>Immunology</i> , 2020 , 161, 200-208 | 7.8 | 2 |
| 48 | Impact of MYC on Anti-Tumor Immune Responses in Aggressive B Cell Non-Hodgkin Lymphomas: Consequences for Cancer Immunotherapy. <i>Cancers</i> , 2020 , 12, | 6.6 | 4 |
| 47 | Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity. <i>Acta Pharmacologica Sinica</i> , 2020 , 41, 1395-1402 | 8 | 10 |
| 46 | Agammaglobulinemia. 2020 , 443-466 | | |
| 45 | Immunological characterization of HM5023507, an orally active PI3K β inhibitor. <i>Pharmacology Research and Perspectives</i> , 2020 , 8, e00559 | 3.1 | 2 |
| 44 | Exploring the controversial role of PI3K signalling in CD4 regulatory T (T-Reg) cells. <i>Advances in Biological Regulation</i> , 2020 , 76, 100722 | 6.2 | 2 |
| 43 | Selective targeting of PI3K β suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. <i>Journal of Autoimmunity</i> , 2020 , 111, 102435 | 15.5 | 10 |
| 42 | A Humanized Lym-1 CAR with Novel DAP10/DAP12 Signaling Domains Demonstrates Reduced Tonic Signaling and Increased Antitumor Activity in B-Cell Lymphoma Models. <i>Clinical Cancer Research</i> , 2020 , 26, 3694-3706 | 12.9 | 6 |
| 41 | Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 181, 233-248 | 4.4 | 6 |

| | | | |
|----|---|------|----|
| 40 | MSCs-released TGF β generate CD4CD25Foxp3 in T-reg cells of human SLE PBMC. <i>Journal of the Formosan Medical Association</i> , 2021 , 120, 602-608 | 3.2 | 17 |
| 39 | Regional heterogeneity in rat Peyer's patches through whole transcriptome analysis. <i>Experimental Biology and Medicine</i> , 2021 , 246, 513-522 | 3.7 | 2 |
| 38 | Tetrabromobisphenol A induces THR β -mediated inflammation and uterine injury in mice at environmentally relevant exposure concentrations. <i>Journal of Hazardous Materials</i> , 2021 , 407, 124859 | 12.8 | 5 |
| 37 | Inhibition of PI3K Isoform p110 α Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity. <i>Cancers</i> , 2021 , 13, | 6.6 | 2 |
| 36 | The Effect of the Clenbuterol- β -Adrenergic Receptor Agonist on the Peripheral Blood Mononuclear Cells Proliferation, Phenotype, Functions, and Reactive Oxygen Species Production in Race Horses In Vitro. <i>Cells</i> , 2021 , 10, | 7.9 | 2 |
| 35 | ICOS signaling limits regulatory T cell accumulation and function in visceral adipose tissue. <i>Journal of Experimental Medicine</i> , 2021 , 218, | 16.6 | 4 |
| 34 | The PI-3-Kinase P110 δ Catalytic Subunit of T Lymphocytes Modulates Collagen-Induced Arthritis. <i>International Journal of Molecular Sciences</i> , 2021 , 22, | 6.3 | 0 |
| 33 | Phosphoinositide 3-Kinase p110 Delta Differentially Restrains and Directs Na β e Versus Effector CD8T Cell Transcriptional Programs. <i>Frontiers in Immunology</i> , 2021 , 12, 691997 | 8.4 | 3 |
| 32 | Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- β and - γ <i>Frontiers in Immunology</i> , 2021 , 12, 718621 | 8.4 | 3 |
| 31 | Phosphorylation of CrkL S114 induced by common gamma chain cytokines and T-cell receptor signal transduction. <i>Scientific Reports</i> , 2021 , 11, 16951 | 4.9 | 0 |
| 30 | Synergistic cytotoxicity of dual PI3K/mTOR and FLT3 inhibition in FLT3-ITD AML cells. <i>Advances in Biological Regulation</i> , 2021 , 82, 100830 | 6.2 | 0 |
| 29 | The PI3K-AKT-mTOR Signaling Network in AML. 2015 , 335-362 | | 1 |
| 28 | PI3K p110 δ is expressed by gp38(-)CD31(+) and gp38(+)CD31(+) spleen stromal cells and regulates their CCL19, CCL21, and LTB β mRNA levels. <i>PLoS ONE</i> , 2013 , 8, e72960 | 3.7 | 2 |
| 27 | A Conditional Knockout Mouse Model Reveals That Calponin-3 Is Dispensable for Early B Cell Development. <i>PLoS ONE</i> , 2015 , 10, e0128385 | 3.7 | 11 |
| 26 | A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo. <i>Oncotarget</i> , 2014 , 5, 3836-48 | 3.3 | 13 |
| 25 | PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors. <i>Oncotarget</i> , 2015 , 6, 10399-414 | 3.3 | 29 |
| 24 | Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth. <i>Cancer Biology and Medicine</i> , 2015 , 12, 401-8 | 5.2 | 6 |
| 23 | Acute Csk inhibition hinders B cell activation by constraining the PI3 kinase pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118, | 11.5 | 0 |

| | | | |
|----|---|-----|----|
| 22 | Can Soluble Immune Checkpoint Molecules on Exosomes Mediate Inflammation?. <i>Journal of NeuroImmune Pharmacology</i> , 2021 , 1 | 6.9 | 0 |
| 21 | Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib. <i>Cancers</i> , 2021 , 13, | 6.6 | 2 |
| 20 | ICOS signaling limits regulatory T cell accumulation and function in visceral adipose tissue. | | |
| 19 | The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. <i>Science Immunology</i> , 2021 , 6, eabf4034 | 28 | 2 |
| 18 | [Combined treatment with myo-inositol and luteolin selectively suppresses growth of human lung cancer A549 cells possibly by suppressing activation of PDK1 and Akt]. <i>Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University</i> , 2018 , 38, 1378-1383 | 0.5 | |
| 17 | [Expression profiles of PI3K, NF- κ B, and STAT1 in peripheral blood mononuclear cells in children with bronchial asthma]. <i>Chinese Journal of Contemporary Pediatrics</i> , 2016 , 18, 614-7 | 0.8 | 3 |
| 16 | CounterAKTing HIV: Toward a "Block and Clear" Strategy?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022 , 12, 827717 | 5.9 | 1 |
| 15 | Targeting PI3K/Akt signal transduction for cancer therapy.. <i>Signal Transduction and Targeted Therapy</i> , 2021 , 6, 425 | 21 | 27 |
| 14 | Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial.. <i>Cancers</i> , 2022 , 14, | 6.6 | 1 |
| 13 | Molybdenum and cadmium co-exposure induces endoplasmic reticulum stress-mediated apoptosis by Th1 polarization in Shaoxing duck (<i>Anas platyrhyncha</i>) spleens.. <i>Chemosphere</i> , 2022 , 134275 | 8.4 | 1 |
| 12 | Role and regulation of autophagy in cancer.. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022 , 166400 | 6.9 | 3 |
| 11 | Data_Sheet_1.PDF. 2018 , | | |
| 10 | Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2699 | 5.1 | 1 |
| 9 | Discovery and pre-clinical characterization of a selective PI3K γ inhibitor, LL-00071210 in rheumatoid arthritis. <i>European Journal of Pharmacology</i> , 2022 , 927, 175054 | 5.3 | |
| 8 | Apolipoprotein A1 Modulates Teff/Treg Balance Through Scavenger Receptor Class B Type I-Dependent Mechanisms in Experimental Autoimmune Uveitis. 2022 , 63, 23 | | 1 |
| 7 | Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions. 2022 , 3, | | 2 |
| 6 | Two-Track Virtual Screening Approach to Identify the Dual Inhibitors of Wild Type and C481S Mutant of Bruton's Tyrosine Kinase. | | 0 |
| 5 | Control of CD4 ⁺ T Cell Differentiation and Function by PI3K Isoforms. 2022 , 197-216 | | 0 |

- 4 Developing PI3K Inhibitors for Respiratory Diseases. **2022**, 437-466 ○
- 3 Advances in T Cells Based on Inflammation in Metabolic Diseases. **2022**, 11, 3554 ○
- 2 The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer. **2022**, 14, 5747 ○
- 1 Mitigating Serious Adverse Events in Gene Therapy with AAV Vectors: Vector Dose and Immunosuppression. ○